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Abstract
We built a novel Bayesian hierarchical survival model based on the
somatic mutation profile of patients across 50 genes and 27 cancer types.
The pan-cancer quality allows for the model to “borrow” information
across cancer types, motivated by the assumption that similar mutation
profiles may have similar (but not necessarily identical) effects on survival
across different tissues-of-origin or tumor types. The effect of a mutation
at each gene was allowed to vary by cancer type while the mean effect
of each gene was shared across cancers. Within this framework we con-
sidered four parametric survival models (normal, log-normal, exponential,
and Weibull), and we compared their performance via a cross-validation
approach in which we fit each model on training data and estimate the
log-posterior predictive likelihood on test data. The log-normal model
gave the best fit, and we investigated the partial effect of each gene on
survival via a forward selection procedure. Through this we determined
that mutations at TP53 and FAT4 were together the most useful for pre-
dicting patient survival. We validated the model via simulation to ensure
that our algorithm for posterior computation gave nominal coverage rates.
The code used for this analysis can be found at http://github.com/
sarahsamorodnitsky/Pan-Cancer-Survival-Modeling, and the results
are at http://ericfrazerlock.com/surv_figs/SurvivalDisplay.html.
Key words: Bayesian hierarchical modeling, Pan-Cancer modeling, Sur-
vival analysis, The Cancer Genome Atlas (TCGA)
1 Introduction
The recently completed Cancer Genome Atlas (TCGA) program has provided
a comprehensive molecular characterization of 33 cancer types from over 10,000
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patients, and the database remains a valuable public resource [1]. The differ-
ent cancer types are generally defined by their tissue-of-origin. The project
has revealed striking heterogeneity in the genomic and molecular profiles across
patients within each cancer type. This heterogeneity is presented in several flag-
ship publications (e.g., see [2, 3, 4]) in the form of molecularly distinct subtypes,
and these subtypes often correlate with clinical endpoints. However, leveraging
molecular heterogeneity for personalized risk prediction on a more granular scale
is limited by the number of patients with reliable clinical data for each cancer
type [5]. Moreover, the effects of individual molecular biomarkers on survival
or other clinical outcomes are often small, and thus predictive analyses within
a single type of cancer are underpowered [6].
In 2013, TCGA began the Pan-Cancer Analysis Project, motivated by the
observation that “cancers of disparate organs reveal many shared features,
and, conversely, cancers from the same organ are often quite distinct” [7, 8].
This initiative has resulted in several studies across multiple cancer types that
have revealed important shared molecular alterations for somatic mutations
[9], copy number [10], mRNA [11], and protein abundance [12]. If these po-
tential biomarkers have similar clinical effects across multiple types of cancer,
then predictive models that are estimated using pan-cancer data will have more
power than models that are fit separately for each type of cancer. The TCGA
Pan-Cancer clinical data resource (TCGA-CDR) [5] has facilitated pan-cancer
models by curating and standardizing available data for four clinical outcomes
(overall survival, disease-specific survival, disease-free interval or progression-
free interval) across all 33 TCGA cohorts.
We propose and implement a novel Bayesian hierarchical framework to pre-
dict survival from multiple molecular predictors that are shared across multiple
cancer types. An important feature of this approach is that it allows for borrow-
ing information across models for each cancer type under the assumption that
shared molecular predictors are likely to have a similar effect on survival progno-
sis, but it also allows sufficient flexibility for the same biomarker to have different
effects depending on the type of cancer. Moreover, the Bayesian framework pro-
vides a principled way to incorporate prior information from other studies or
cohorts, which is well-motivated given the vast body of literature on molecular
biomarkers in cancer.
Using our proposed framework, we developed a pan-cancer predictive model
for overall survival (OS), using the somatic mutation profile of each tumor as
the primary predictors of interest. We used OS because it is unambiguously
defined and is available for almost all types of cancer, despite short follow-up
times [5]. We focus on somatic mutations because they play a critical role in
the development of many cancer types [13], are available for all cohorts in the
TCGA database, and are straightforward to compare across different tissues-of-
origin. A pan-cancer analysis of somatic mutations across 12 different cancer
types from TCGA revealed several genes that have frequent mutations across
multiple types of cancer [9]. Their analysis also considered the marginal effect of
each gene on OS, via cox proportional hazards models for (1) each cancer type
separately and (2) for a fully joint model with all cancer types together; our
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approach aims to compromise between these two strategies. For our application
we consider the somatic mutation status of 50 genes, and survival data for
5698 patients comprising 27 different types of cancer. We evaluate and compare
several different potential models via a robust cross-validation approach to assess
predictive accuracy for this dataset.
The rest of this article is organized as follows. In the Methods section, we
discuss how the data were collected and our approach to filtering out cancer
types and genes. We also describe our modeling framework, how we selected
the survival distribution we chose to use in our analysis, and our Gibbs sampling
algorithm to calculate the posteriors of the model parameters. In the Results
section, we discuss the results of our model selection procedure and our approach
to determining which genes were most predictive of survival. Using the results
from these two processes, we show the resulting credible interval estimates of our
parameters and display survival curves. In the Discussion section, we discuss
our results and future work that builds on this study for pan-cancer survival
modeling.
2 Methods
2.1 Data Acquisition and Processing
We acquired clinical data for each patient via the Cancer Genome Atlas Clinical
Data Resource (TCGA-CDR)[5], which includes data for 33 cancer types and
over 11,160 patients. We acquired genome wide somatic mutation data through
the TCGA2STAT package for R[14], which gathers data from the Broad In-
stitute GDAC Firehose. The curated mutation data were available for 27305
genes and 5793 patients with a binary indicator for whether there was a somatic
non-silent mutation (0=no, 1=yes) within the coding region of each gene.
We first matched the observations in the CDR dataset with the muta-
tion data obtained through TCGA2STAT. If any patients were present in one
dataset but not the other, that observation was removed from the study. We
also removed any observations that had a negative survival time, a survival
time entered as 0, or who were missing both a survival time and an entry for
time-to-last-contact. We chose to eliminate five cancer types from our study
due to high (> 90%) censoring rates, meaning patients survived longer than
the duration of the study and their outcome status is unknown. These five
types were Pheochromocytoma and Paraganglioma (PCPG), Prostate adeno-
carcinoma (PRAD), Testicular Germ Cell Tumors (TGCT), Thyroid carcinoma
(THCA), and Thymoma (THYM). The TCGA-CDR also caution against using
OS as an endpoint for these cancer types, due to the lack observed survival
events. One other cancer type, Mesothelioma (MESO), did not have any so-
matic mutation data available through the TCGA2STAT pipeline, so it was also
omitted from our analysis.
The following 27 cancer types remained in our study: Adrenocortical carci-
noma (ACC), Bladder Urothelial Carcinoma (BLCA), Breast invasive carcinoma
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(BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma
(CESC), Cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Lym-
phoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), Esophageal carci-
noma (ESCA), Glioblastoma multiforme (GBM), Head and Neck squamous cell
carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney renal clear cell car-
cinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), Acute Myeloid
Leukemia (LAML), Brain Lower Grade Glioma (LGG), Liver hepatocellular
carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell car-
cinoma (LUSC), Ovarian serous cystadenocarcinoma (OV), Pancreatic adeno-
carcinoma (PAAD), Rectum adenocarcinoma (READ), Sarcoma (SARC), Skin
Cutaneous Melanoma (SKCM), Stomach adenocarcinoma (STAD), Uterine Cor-
pus Endometrial Carcinoma (UCEC), Uterine Carcinosarcoma (UCS), Uveal
Melanoma (UVM).
We filtered the genes based on average mutation rate across the 27 cancer
types, selecting the top 50 mutated genes. In this way, each cancer type was
weighted the same in calculating the mean mutation rate. This also ensured
that each gene would be represented across most cancers, not just within a
few. As a result, certain genes which are highly mutated in particular can-
cers but not in others were excluded. The genes we incorporated in our study
were ABCA13, AHNAK2, APC, APOB, ARID1A, CSMD1, CSMD2, CSMD3,
DMD, DNAH11, DNAH5, DNAH7, DNAH8, DNAH9, DST, FAT1, FAT3,
FAT4, FLG, FRG1B, GPR98, HMCN1, KRAS, LRP1B, LRP2, MACF1, MLL2,
MLL3, MUC16, MUC17, MUC2, MUC4, MUC5B, NEB, OBSCN, PCDH15,
PCLO, PIK3CA, PKHD1L1, PTEN, RYR1, RYR2, RYR3, SPTA1, SYNE1,
TP53, TTN, USH2A, XIRP2, and ZFHX4. The average rate of mutation for
these genes across the 27 cancer types is summarized in Table 1. In total, we
used mutation data from 5698 patients.
We considered the correlation of mutation status between genes across all
cancers, for exploratory purposes and to investigate potential issues of multi-
collinearity for polygenic models. Figure 1 shows a pairwise correlation plot
for all genes considered using mutation status across all patients included in
this study. The Pearson correlation coefficients between genes were uniformly
positive but relatively week, ranging from r = −0.07 to r = 0.32. The pos-
itive correlations were expected as the total mutation burden can vary across
patients; however, the relative weakness of the correlations suggests that each
individual gene may provide unique information and multicollinarity is not a
concern. These correlations may change considerably if one were to consider
only a single type of cancer or a subset of related cancers.
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Gene Mutation Rate
TP53 0.357
TTN 0.296
MUC16 0.192
MUC4 0.124
PIK3CA 0.116
CSMD3 0.116
LRP1B 0.115
SYNE1 0.110
KRAS 0.108
FLG 0.105
RYR2 0.104
USH2A 0.098
PCLO 0.095
APC 0.094
DNAH5 0.093
MUC5B 0.089
FAT4 0.088
OBSCN 0.088
CSMD1 0.084
MUC17 0.084
ZFHX4 0.084
HMCN1 0.083
ARID1A 0.080
GPR98 0.080
FAT3 0.077
Gene Mutation Rate
LRP2 0.077
XIRP2 0.077
AHNAK2 0.077
MLL2 0.077
SPTA1 0.076
APOB 0.076
PTEN 0.076
MLL3 0.075
FRG1B 0.074
PKHD1L1 0.073
DST 0.070
DMD 0.070
RYR3 0.070
MUC2 0.070
NEB 0.067
RYR1 0.066
MACF1 0.066
PCDH15 0.066
ABCA13 0.066
DNAH9 0.064
FAT1 0.064
DNAH8 0.063
DNAH11 0.062
CSMD2 0.061
DNAH7 0.060
Table 1: Summary of Genes and Average Mutation Rate
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Fig. 1 Correlation plot for correlations between somatic mutation statuses
across tissue types
2.2 Model
We propose a Bayesian hierarchical model for patient survival that incorporates
binary mutation status variables and age across 27 cancer types. The multi-layer
nature of our model allows the effect of a mutation at each gene to vary by cancer
type, while simultaneously inferring the mean and variance of these effects.
Thus, the model facilitates the borrowing of information across cancer types by
shrinking the estimated effects towards a common mean. Our model can also
accommodate censored observations, as discussed in the following subsection.
We use the following notation in our framework: yij is the (potentially censored)
survival time for patient j in cancer type i, j = 1, . . . , ni, i = 1, . . . , 27. xijp is
the centered age if p = 1 and is the mutation status for gene p−1, p = 2, . . . , 51.
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We consider four different likelihood models for survival:
yij ∼ Normal(λij , σ2)
yij ∼ Log-normal(λij , σ2)
yij ∼ Exponential( 1
λij
)
yij ∼Weibull(α, 1
λij
).
For each likelihood we consider a hierarchical linear model for λij :
λij = βi0 + xij1βi1 + xij2βi1 + · · ·+ xij51βi51
where βip is the linear effect of age if p = 1 and mutation at gene p − 1 on
survival if p = 2, . . . , 51 for a patient with cancer type i. This approach extends
commonly used parametric Bayesian survival models [15], and to complete the
Bayesian framework we specify prior distributions for the unknown parameters.
For the Normal and Log-normal models, we used an Inverse-Gamma(0.01, 0.01)
prior distribution for the residual variation of survival times within each cancer
type, σ2. For the Weibull model, we used a Uniform(0, 5) prior for the shape
parameter, α. Under the assumption that a mutation at one gene or an increase
in one year of age may affect survival differently depending on the type of cancer,
the linear effect of age and each mutation, βip, was assumed to vary by cancer
type. We assume
βip ∼ Normal(β˜p, λ2p) for p = 0, . . . , 51.
where β˜p is the mean effect on survival across cancer types and λp describes the
extent to which the effects vary across the different types. Thus, β˜i0 gives the
mean intercept and βi0 is an intercept that describes the baseline survival for
type i. Similarly, β˜p is the average effect on survival for age if p = 1 and for mu-
tation at a gene if p = 2, . . . , 51. For all coefficients and all models, we gave the
mean effects independent and diffuse normal priors: β˜p ∼ Normal(0, 100002).
The parameters λ2p are important because they indicate the degree of effect het-
erogeneity across cancer types; we used Inverse-Gamma (0.01, 0.01) priors for
each λ2p.
2.3 Parameter Estimation
Depending on the survival model, we employed a different approach to infer the
posterior for model parameters. The log-normal and normal models were fit in
R using an in-house Gibbs sampler. The sampler is described below however
more details can be found in Appendix 1.
1. Initialize β˜
(0)
p , λ
2(0)
p , σ2(0). Initialize all censored observations at their
time-of-last-contact.
For samples t = 1, ..., 20000, repeat the following steps:
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2. Draw β
(t)
ip from P (β
(t)
ip |β˜(t−1), λ2(t−1), σ2(t−1)) for i = 1, . . . , 27 and p =
0, . . . , 51.
3. Draw λ
2(t)
p from P (λ
2(t)
p |β(t)ip , β˜(t−1)) for p = 0, . . . , 51.
4. Draw β˜
(t)
p from P (β˜
(t)
p |β(t)ip , λ2(t)p ) for p = 0, . . . , 51.
5. Draw σ2(t) from P (σ2(t)|β(t)ip ) for for i = 1, . . . , 27 and p = 0, . . . , 51.
6. Generate survival times for censored observations using β
(t)
i1 , ..., β
(t)
ip , σ
2(t)
• If assuming the data follows a normal distribution, generate survival
times for censored observations from a normal distribution with mean
β
(t)
i0 + β
(t)
i1 xij1 + · · · + β(t)i51xij51 and variance σ2(t) that is truncated
at the time-of-last-contact for observation ij.
• If assuming the data follows a log-normal distribution, generate sur-
vival times from a normal distribution with mean β
(t)
i0 + β
(t)
i1 xij1 +
· · · + β(t)i51xij51 and variance σ2(t) that is truncated at the log of the
time-of-last-contact for observation ij.
We ran the sampler for 20000 iterations and used a 10000 iteration burn-in
to ensure convergence of the parameters. In the Appendix 2 of this article, we
describe how we validated this model fitting procedure.
Posterior samples for the exponential and Weibull models were obtained
using the Just Another Gibbs Sampler (JAGS) software[16]. For these models,
we ran the sampler for the same number of iterations and employed the same
burn-in as for the normal and log-normal models above. In all calculations based
on the posteriors of our Gibbs sampler and our JAGS models, we thinned by
every 10th iteration to speed up computing time and memory efficiency.
2.4 Model Selection
To assess which of the normal, log-normal, exponential, and Weibull models was
the best fit for the data, we calculated the log out-of-sample posterior predictive
likelihood in a 5-fold cross validation procedure, as described below.
Consider the kth training-test partition of the data, k = 1, . . . , 5 such that
~Y = {~Y traink , ~Y testk } . Let p(y|X) be the probability distribution for survival
time. On each training fold, we fit the model and generated posterior samples
for each parameter. For each posterior sample after burn-in, we computed
P (~Y test|Θto) =
∏
(i,j)
uncensored
p(yij |Θto)
∏
(i,j)
censored
Pr(yij > y
c
ij | Θto)
where Θto is a vector of all the tth iteration posterior samples for the parameters
of the probability distribution of survival and ycij is the censor time for the jth
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patient in the ith cancer type. After computing this quantity for each iteration,
we computed an estimate of the out-of-sample posterior predictive likelihood:∫
P (~Y test|Θ0)P (Θ0|~Y train)dΘ0 ≈ 1
T
T∑
t=1
P (~Y test|Θt)
where T is the number of sampling iterations after burn-in and thinning. As
stated previously, we chose to thin by every 10th iteration to ease computing
time. As a result, this value was calculated based on 1000 Gibbs sampling
iterations. After calculating the log-posterior predictive likelihood on each test
fold, we took the average likelihood and compared the four models.
2.5 Forward Selection
To assess the partial improvement of each gene in predicting survival, we con-
structed a forward selection approach that would allow us to see which genes
were most important in predicting survival across all cancer types. In this way,
we were able to determine the relative importance of each gene, and achieve a
more parsimonious predictive model. For our forward selection approach, we
used the same out-of-sample log-posterior likelihood metric described in the pre-
vious section on model comparison. Our forward selection method proceeded
as follows:
1. Calculate the average log-posterior predictive likelihood for the null model
(with age and cancer type intercepts, but no genes) fit on each of the 5-
folds.
2. For each gene, consider the model with only the intercept, age, and that
gene included. Calculate the log-posterior predictive likelihood under this
model using 5-fold cross validation.
(1) Select the gene that produced the model with the highest log-posterior
predictive likelihood. Call this model M1.
(2) Compare the likelihood for this model with the null model; if the
likelihood has increased, proceed by adding this gene to the model.
Otherwise, stop.
3. For each remaining gene, add that gene separately to model M1 and cal-
culate the resulting mean log-posterior predictive likelihood using 5-fold
cross validation.
(1) Select from the resulting two gene models the gene that maximized
the log-posterior likelihood. Call this model M2
(2) Compare the log-posterior likelihood for M2 to M1. If the likelihood
has increased, add the new gene to the model and proceed. Other-
wise, stop.
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4. Continue until the log-posterior predictive likelihood ceases to increase.
At this point, the final model has been found.
Once a final model had been found, we investigated the effects of each mu-
tation on survival through credible interval plots and survival curves, described
further in the Results section.
3 Results
3.1 Model Selection
The results of the comparison described in the Methods section are shown in
Table 2. We found that the log-normal model had the highest out-of-sample
log-posterior likelihood out of the Normal, Exponential, and Weibull models.
We assumed a log-normal distribution of survival for the remainder of our in-
vestigation.
Model Log Posterior Likelihood
Log-Normal -3667.139
Normal -3918.152
Exponential -7123.648
Weibull -7212.59
Table 2: Out-Of-Sample Posterior Predictive Likelihood
In this model, the coefficients are inferred by borrowing information across
cancer types. However, we considered an analogous log-normal model in which
the coefficients were inferred independently for each cancer type to compare
with the model we selected here. We used the same uninformative prior on each
coefficient as the one assumed for β˜ : βij ∼ N(0, 100002). However, our in-
house Gibbs sampler under this model failed to converge after 30000 iterations
for several coefficients. This demonstrates a drawback to not borrowing across
cancer types as our proposed model does.
3.2 Forward Selection
Table 4 displays the mean log-posterior predictive likelihoods for each step in
the forward selection procedure. Every model is adjusted for patient age.
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Covariates in Model Mean Log Posterior Likelihood
Age, No Genes -5014.895
Age, TP53 -1009.63
Age, TP53, FAT4 -1009.135
Age, TP53, FAT4, DNAH5 -1009.179
Table 3: Results from Forward Selection Procedure
The log-posterior likelihood for the null model, meaning the model with only
age as a predictor, was −5014.895. The model with TP53 added yielded a dra-
matic improvement, with a log-posterior likelihood value of −1009.63. The next
gene to be added was FAT4, yielding a log posterior likelihood of −1009.135.
At this point, the posterior likelihood stopped improving. DNAH5 was last to
be added, and the model with TP53, FAT4, and DNAH5 as predictors led to a
log-posterior likelihood of −1009.179. We validated convergence of the forward
selection procedure by running the process several times to ensure we obtained
the same result. Across all 27 cancers, TP53 was mutated in an average of
36.9% of patients, the highest of all genes, and FAT4 in 8.8% (Table 1). The
appearance of TP53 here is not surprising (see the Discussion section). How-
ever, we note that after the inclusion of TP53, the improvement in likelihood
by FAT4 was marginal. This final model from our forward selection procedure
served as our basis of exploration for subsequent analysis.
We also used our forward selection approach without including TP53 as
a potential covariate to see what genes would be added. Our results were as
follows:
Covariates in Model Mean Log Posterior Likelihood
Age, No Genes -5014.895
Age, APOB -1011.321
Age, APOB, ARID1A -1011.694
Table 4: Results from Forward Selection Procedure Without TP53
Without including TP53 as a possible covariate, the first gene to be added
was APOB, leading to a log-posterior likelihood of −1011.321. The addition
of ARID1A on top of APOB led to the highest log-posterior likelihood of all
genes at −1011.694 though this metric ceased to increase at this point. Of the
patients in our study, 7.6% had a mutation at APOB.
3.3 Credible Intervals for Model Coefficients
To understand the magnitude and direction of the partial effect of age and a
mutation at a gene on patient survival, we computed and visualized the 95%
credible interval based on posterior samples for each βip. The intervals we show
here were calculated from the multivariate log-normal model resulting from the
forward selection procedure, with cancer type intercepts, age, TP53, and FAT4
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included as predictors. The credible intervals for each βip can be found in
Table 5.
Figure 2 displays the credible intervals across cancer types for each param-
eter in the model. Panel 2a compares the baseline survival across the different
cancer types. Panel 2b reveals the generally deleterious effect of age on patient
survival, as indicated by the highlighted red intervals. For the majority of can-
cers, an increase in age led to a decrease in survival; however, the extent to
which age has an effect is not homogeneous or precisely identified for every can-
cer. For breast cancer (BRCA), the impact of age is more certain, indicated by
a narrower credible interval, compared to the effect of age on patients with (e.g.)
uterine carcinosarcoma (UCS). Similarly, Figure 2c shows the estimated effect of
a TP53 mutation on survival across cancers, and the estimated effect was gener-
ally negative for most cancers. This, again, demonstrates a poorer prognosis for
patients with a mutation at TP53. Breast cancer (BRCA) and head-neck squa-
mous cell carcinoma (HNSC) had estimated TP53 effects with credible bounds
entirely below 0, and adrenocortical carcinoma (ACC) was nearly entirely below
0. FAT4 mutation credible intervals (Figure 2d) appeared to be more positive
than those of TP53, with some intervals entirely above 0.
Cancer Intercept Age FAT4 TP53
1 ACC (7.616, 8.347) (-0.033, 0.007) (-0.347, 0.67) (-1.146, 0.020)
2 BLCA (6.677, 7.379) (-0.059, -0.005) (-0.162, 0.732) (-0.654, 0.180)
3 BRCA (8.675, 9.021) (-0.036, -0.015) (-0.233, 0.771) (-0.590, -0.037)
4 CESC (7.757, 8.313) (-0.030, 0.011) (-0.226, 0.849) (-0.558, 0.691)
5 CHOL (6.402, 7.381) (-0.047, 0.019) (-0.745, 0.547) (-0.537, 0.739)
6 COAD (7.348, 8.134) (-0.044, 0.010) (-0.317, 0.614) (-0.533, 0.377)
7 DLBC (7.65, 8.721) (-0.037, 0.031) (-0.266, 0.812) (-0.633, 0.765)
8 ESCA (6.412, 7.284) (-0.033, 0.005) (-0.339, 0.539) (-0.537, 0.351)
9 GBM (5.657, 6.036) (-0.043, -0.017) (-0.462, 0.655) (-0.053, 0.624)
10 HNSC (7.225, 7.906) (-0.042, -0.013) (0.016, 0.957) (-0.991, -0.222)
11 KICH (8.662, 9.781) (-0.074, -0.003) (-0.308, 0.832) (-1.000, 0.180)
12 KIRC (7.724, 8.054) (-0.052, -0.025) (-0.443, 0.685) (-0.858, 0.358)
13 KIRP (7.941, 8.611) (-0.016, 0.034) (-0.406, 0.727) (-0.893, 0.431)
14 LAML (6.213, 6.666) (-0.053, -0.025) (-0.347, 0.843) (-1.079, 0.028)
15 LGG (7.676, 8.306) (-0.072, -0.038) (-0.282, 0.909) (-0.369, 0.429)
16 LIHC (6.761, 7.257) (-0.024, 0.008) (-0.154, 0.94) (-0.668, 0.108)
17 LUAD (7.188, 7.742) (-0.032, 0.010) (-0.174, 0.634) (-0.603, 0.122)
18 LUSC (6.549, 7.36) (-0.054, -0.003) (-0.229, 0.628) (-0.189, 0.695)
19 OV (6.963, 7.568) (-0.048, -0.015) (-0.280, 0.906) (-0.334, 0.356)
20 PAAD (6.302, 7.071) (-0.039, 0.004) (-0.476, 0.572) (-0.588, 0.238)
21 READ (7.376, 8.58) (-0.056, 0.025) (-0.196, 0.962) (-0.556, 0.606)
22 SARC (7.37, 7.844) (-0.032, -0.004) (-0.294, 0.842) (-0.326, 0.386)
23 SKCM (7.537, 7.927) (-0.032, -0.011) (-0.181, 0.425) (-0.266, 0.515)
24 STAD (6.495, 7.033) (-0.034, 0.003) (0.044, 0.796) (-0.244, 0.452)
25 UCEC (8.467, 9.097) (-0.038, 0.008) (0.061, 1.212) (-0.786, 0.099)
26 UCS (6.270, 7.518) (-0.079, -0.007) (-0.269, 0.835) (-0.627, 0.537)
27 UVM (7.268, 8.046) (-0.069, -0.010) (-0.303, 0.909) (-0.856, 0.574)
Table 5: Credible Intervals for Model Coefficients Across Each Cancer Type
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Fig. 2 Credible Intervals By Covariate and Cancer Type
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Covariate Mean Effect
Intercept (7.213, 7.870)
Age (-0.037, -0.008)
FAT4 Mutation Status (0.031, 0.480)
TP53 Mutation Status (-0.316, 0.056)
Table 6: Credible Intervals for Mean of Model Coefficients
3.4 Credible intervals for Mean Mutation Effect
We also studied the credible intervals for the mean effect of each covariate. The
mean effect for each predictor, β˜p, was assumed constant across cancer types
and the individual effect by tumor varied around this mean. The results for β˜p
are given in Table 6 and shown in Figure 3.
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Fig. 3 Visual display of the credible intervals for β˜p, p = 1, . . . , 5
These results indicate the effect of each covariate averaged across cancers;
therefore, if a predictor was more potent in one cancer and less so in another,
this may not necessarily be represented in estimates for the mean effect. This
substantiates why we chose to allow the effect of each covariate to differenti-
ate by tumor type. The credible intervals for age and TP53 mutation status
coincide with the βip interval results as both had entirely negative or nearly
entirely negative interval estimates for their respective means. The interval for
FAT4 also coincides with the βip intervals; however, its comparably large width
demonstrates a lack of certainty on its effect with age and TP53 in the model.
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3.5 Survival Plots
To visualize the impact of age and a mutation at each of TP53 and FAT4, we
show here survival curves computed based on each combination of predictor
values. The full collection of survival curves, for any cancer type and any com-
bination of predictors, are available online at http://ericfrazerlock.com/
surv_figs/SurvivalDisplay.html. The plots displayed in Figure 4 are for a
combination of covariates for patients with adrenocortical carcinoma (ACC), for
which we had data on 89 tumors. In our dataset, patients with ACC ranged in
age from 14 years old to 72 years old, with a median age of 49. The mutation
rates for patients with ACC are as follows: 50.6% had no mutations in FAT4 or
TP53, 10.1% had mutations in just FAT4, 19.1% had mutations at just TP53,
and 4.49% had mutations in both. The impact of the negative coefficient of
TP53 is demonstrated in these plots, as prognosis seems to worsen over 5 years
if a patient has such a mutation. The deleterious effect of age is also visible,
which is to be expected. The seemingly positive effect of FAT4 is also apparent,
with calculated survival curves appearing higher compared to those for patients
with no mutations at TP53 and FAT4.
Fig. 4 Survival curves under different covariate combinations for ACC with
ages overlaid. Estimates for 30 year old patients are shown in black, 50 year
olds in orange, and 80 year olds in blue. 95% error bounds are shown in dotted
lines.
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4 Discussion
In this article, we propose a novel Bayesian hierarchical model for cancer patient
survival based on age and mutation status. This model is unique in its ability to
allow the effect of each covariate to vary by cancer type. This framework is mo-
tivated by the assumption that similar genetic profiles may have similar, though
not necessarily identical, effects on patient survival across tissue-of-origin. This
work may be extended to allow for other clinical covariates to be added to the
model, such as stage and grade, and allows the user to adjust the effect of each
predictor by cancer type as informed by prior knowledge.
To determine which genes were most important in survival prediction, we
used a forward selection procedure that added TP53 and FAT4 to our model.
The inclusion of TP53 led to a dramatic improvement in the model fit, while
each additional gene reduced the log-posterior likelihood by a marginal amount.
This indicates that TP53 is largely the most predictive, which is natural given its
high mutation rate across cancer types (see Table 1). In particular, robust effects
for TP53 were observed for breast cancer (BRCA) and head-neck squamous cell
carcinoma (HNSC); the basal-like subtype for BRCA[2] and the HPV-negative
subtype for HNSC[17] are almost universally TP53 -mutated and have relatively
poor outcomes. Moreover, there is a vast literature on the mechanistic role of
TP53 in cancer progression as an agent of DNA repair [18] and in maintenance of
genome integrity. It was also encouraging to see TP53 added to the model as it
is considered a tumor driver gene[19]. FAT4 appears to be much less predictive
than TP53, given its marginal increase in the log-posterior likelihood (from -
1009.63 to -1009.135). It is of note that the credible intervals for coefficient in
the model were largely positive, despite the existence of literature concluding
FAT4 functions as a tumor suppressor [20, 21]. A potential explanation is that
mutations in FAT4 contribute to the development of certain cancers, but these
cancers are comparatively less aggressive than those that arise from mutations
in TP53 or other driver genes. An analysis without TP53 achieved comparable
predictive performance under our hierarchical model via the inclusion of APOB,
suggesting that even genes with lower mutation rates can improve performance.
Using the most frequently mutated genes across genome sequencing cohorts
often also includes known false positives. Comparing our list of genes with Bailey
et al[19], we found that 19/50 were on known false positive lists. However, it
was encouraging to see that these known false positives did not make the final
survival model. However, our gene set also did not include some known tumor
driver genes due to our approach of restricting the genes of interest to those
with mutations across the PanCancer cohort.
In addition, we considered the possibility of collinearity between mutation
status variables, prompting us to investigate the correlation levels between vari-
ables across all cancer types (Figure 1). Based on this plot, we concluded
mutation statuses across all cancer types were not highly associated. However,
the results may look different if one is not considering the cancers in aggregate.
With that in mind, we propose in future work sorting genes differently to meet
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the interest of the researchers, i.e. exploring genes that are known to be highly
mutated in a set of related cancers. In such an instance, it may be necessary to
consider collinearity between variables and adjust accordingly.
We also assessed the predictive quality of our model by calculating survival
curves for each cancer type based on combinations of age and mutation status
based on our model. These plots demonstrated the largely negative effect of
increasing age and a TP53 mutation and the less noticeable effect of FAT4.
Irrespective of mutation status, the survival curves demonstrate the clear effect
age has on survival prognosis, which does not come as much of a surprise.
We created a web-based app that allows users to toggle with cancer types and
predictors to see what 5-year prognosis is predicted to be. Such a tool may be
interesting for academic purposes only.
In our study, we used the TCGA2STAT R package to import TCGA somatic
mutation data due to its convenience in data dissemination, providing somatic
mutation data in a ready-to-use format for statistical analysis. While the pack-
age does offer convenience, we were not able to acquire data for Mesothelioma,
which is available through the TCGA Multi-Center Mutation-Calling in Multi-
ple Cancers (MC3) dataset and through the NCI’s Genome Data Commons. In
the interest of ease of future replication of this study, using the TCGA2STAT
dataset may make it simpler for scientists to acquire the same data we used.
We also did not distinguish the genes we used based on driver mutation status,
false positive status, or otherwise.
In future studies, it would be interesting to apply the model to a subset of the
27 cancer types we selected in order to group cancers that may be more similar
in genetic nature or otherwise. This may elucidate genes unique to predicting
patient survival outcome to specific cancer groupings. Interactions between
covariates could also be included in the model to assess their relationship to
overall survival. It would also be interesting to investigate alternate approaches
to selecting genes to incorporate in the model, possibly incorporating prior
knowledge on driver mutation status or false positive status.
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A Appendix 1: Additional Model Fitting Algo-
rithm Details
We used an in-house Gibbs sampler to estimate the parameters of our proposed
log-normal and normal survival models. At each iteration of our sampler, we
drew a sample of a parameter from its respective conditional posterior distri-
bution. The conditional posterior distributions for each parameter are outlined
below:
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~βi | (Xi, yi, β˜, σ2, λ2) ∼ Normal([ 1
σ2
XTi Xi +
1
λ2
I]−1[
1
σ2
XTi yi +
1
λ2
β˜],
1
σ2
XTi yi +
1
λ2
β˜)
where ~βi is the vector of coefficients for the ith cancer type, Xi is the design
matrix for the ith cancer type, yi is the vector of survival times for the ith cancer
type with the censored observations replaced by their time-of-last-contact, β˜ is
the vector of coefficient parameter means, and λ2 is the vector of variances for
each coefficient parameter.[22]
λp | (~βi, β˜) ∼ Inverse-Gamma(K
2
+ 0.01, 0.01 +
1
2
W )
for p = 1, . . . , P , P being the number of coefficients in the model, i =
1, . . . ,K and whereK = 27, the number of cancer types andW =
∑27
i=1(
~βi−β˜)2.
β˜p | (~βi, λ2p) ∼ Normal(
Kτ2β¯p
λ2p +Kτ
2
,
λ2pτ
2
λ2p +Kτ
2
)
where β¯p is the average coefficient for covariate p across all cancer types,
τ2 = 100002.
σ2 | (Xi, yi) ∼ Inverse-Gamma(N
2
+ 0.01,
1
2
B + 0.01)
where N is the total number of observations in the model and B =
∑K
i=1(yi−
Xi ~βi)
2.
B Appendix 2: Validation Study
In fitting the normal and log-normal models, we ran our own Gibbs sampling
algorithm to generate posteriors for each of the parameters. To validate that
our sampler was running properly, we generated true values for each parame-
ter which we used to generate simulated data. Using this data, we computed
posteriors for each parameter, calculated 95% credible intervals, and checked
whether the true value of the parameter was contained within the interval. The
entire algorithm in more detail is outlined below:
1. For i in 1, . . . , 1000 iterations,
• Initialize a counter at 0 to store the number of iterations out of 1000
for which a parameter has been contained in its calculated credible
interval.
• Generate values of predictors from N(0, 1) to be stored in matrix X
and generate ”true” values for each parameter, ~β0,
~˜
0β, λ
2
0, σ
2
0 from its
respective prior distribution.
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– Based on initial values of parameters, generate survival times
from a normal distribution with mean X ~β0 and variance σ
2
0 .
Generate censor times from the same distribution.
– Replace survival times for observations whose censor time is less
than its survival time with NAs to indicate that that observation
has been censored.
• Using simulated data, run the algorithm as described in section 2.
We chose to generate 2000 posterior samples.
• Once samples have been generated, calculate 95% credible intervals
for each parameter.
– Using the ”true” values, check if the calculated credible interval
covers the true value of the parameter. If so, update the counter
for this parameter by one.
2. Ensure that for approximately 95% of the 1000 iterations, the credible
interval covered the true value of the parameter.
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